The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

5-Amino-1MQ

Research chemical · Grade C

Goals
muscle, weight-loss, mitochondria
Evidence
0 RCT / 4 animal / 3 in vitro
Routes
oral
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
Half-life
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Cardarine

Research chemical · Grade C

Goals
muscle, weight-loss, mitochondria
Evidence
3 RCT / 5 animal / 3 in vitro
Routes
oral
WADA
S4
FDA
Not approved
Cancer caution
hard-stop
Typical dose
Half-life
Half-life in humans: approximately 16-24 hours, supporting once-daily dosing
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

SLU-PP-332

Research chemical · Grade C

Goals
muscle, weight-loss, mitochondria
Evidence
0 RCT / 6 animal / 2 in vitro
Routes
oral
WADA
S4
FDA
Not approved
Cancer caution
none
Typical dose
Half-life
The compound also had sufficient pharmacokinetic properties (oral bioavailability ~45% in rodents, half-life ~8-10 hours) to work as an in vivo tool — it could be given orally t…
Primary mechanism
Activates all three estrogen-related receptors (ERRα, ERRβ, ERRγ) with highest potency for ERRα (EC50 = 98 nM).
View full report →

ATX-304

Research chemical · Grade C

Goals
weight-loss, mitochondria
Evidence
1 RCT / 6 animal / 3 in vitro
Routes
oral
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
Half-life
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →